Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Rachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Journal of Clinical Oncology|2023Cited by 53
TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerRachel O. Abelman, Aditya Bardia, Caroline Weipert et al.|Clinical Cancer Research|2025Cited by 39
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancerArielle J. Medford, Aditya Bardia, Taronish D. Dubash et al.|npj Precision Oncology|2019Cited by 30
Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker AnalysisRachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Cancer Research|2024Cited by 21
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2Rachel O. Abelman, Aditya Bardia, Arielle J. Medford et al.|The Cancer Journal|2022Cited by 12